In an oral presentation of data from its Phase 1/2 AML trial of GMI-1271 at the American Society of Hematology Annual Meeting (ASH), GlycoMimetics reported: Improvements in median overall survival compared to historical matched controls for two AML patient populations Improvements in other clinical
Primary endpoint for single pivotal clinical trial will be overall survival Top-line data expected Q4 2020 Multiple clinical readouts planned starting year-end 2018 and through 2019 and 2020 Details on Phase 3 development plan tomorrow as part of YE financial results conference call: scheduled for
Discussion to focus on Phase 3 development plans for GMI-1271 in AML ROCKVILLE, Md. --(BUSINESS WIRE)--Feb. 27, 2018-- GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to provide an update on development plans for GMI-1271 in acute myeloid leukemia
Trial in patients with AML and “unfit” for chemotherapy, as well as those with Myelodysplastic Syndrome ( MDS), expands potential indications for GMI-1271 and complements planned GlycoMimetics -sponsored registration trial in patients with relapsed/refractory AML Company on track to disclose
ROCKVILLE, Md. --(BUSINESS WIRE)--Dec. 15, 2017-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that it will be included in the NASDAQ Biotechnology Index® (NBI). The annual re-ranking of the NASDAQ Biotechnology Index will be effective prior to market upon on Monday, December 18, 2017 .
Clinical outcomes, including durability of remission and median overall survival, in high-risk patients plus safety and tolerability data presented in oral presentation at American Society of Hematology Annual Meeting and Expo Second oral presentation highlights underlying, differentiated mechanism
ROCKVILLE, Md. --(BUSINESS WIRE)--Nov. 9, 2017-- GlycoMimetics, Inc. (Nasdaq:GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows: STIFEL 2017 HEALTHCARE CONFERENCE When: November 14, 2017 at 8:00
Ongoing discussions with U.S. Food and Drug Administration ( FDA ) regarding regulatory path for GMI-1271, including planned Phase 3 trial initiation in mid-2018 Pro forma cash balance of $132.1 million as of September 30 Two abstracts accepted as oral presentations at the 2017 American Society of
ROCKVILLE, Md ,--(BUSINESS WIRE)--Nov. 1, 2017-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2017 financial results on Wednesday, November 8, 2017 , at 8:30 a.m. ET .
GMI-1271 improves efficacy and safety of chemotherapy in Phase 1/2 study in two acute myeloid leukemia (AML) patient populations Preclinical data detail underlying mechanism for GMI-1271’s ability to enhance sensitivity to chemotherapy GlycoMimetics will review the GMI-1271 clinical data during a